invivodata was advised by Crosstree and represents the firm's fourteenth pharmaceutical technology and technology-enabled solutions transaction.
Please direct inquiries to:
Shane C. Senior, CFA
Managing Director
Crosstree Capital Partners, Inc.
(813) 774-4755
With changes in healthcare legislation, continued drug pricing pressures throughout the world, and regulatory guidance driving demand for electronic patient reported outcomes (ePRO) and Clinical Outcome Assessments (COA), invivodata was a beacon of profitable growth in an otherwise challenging market.
As invivodata’s surging growth was causing it to overtake the previous market leader, its directors elected to retain Crosstree to explore options for a sale. Crosstree assisted the company in executing a competitive, highly targeted “soft auction” process that resulted in several attractive alternatives. invivodata elected to sell to ERT based on a combination of valuation and strategic and cultural fit.
Crosstree believes invivodata’s leading ePRO solution immediately positions ERT as the market leader in COA. The invivodata acquisition provides ERT with an unrivalled portfolio of technology-enabled services. It enhances ERT’s multi-mode ePRO product range and bolsters ERT’s position as the scientific thought leader in health outcomes research while complementing its market-leading position in cardiac safety and respiratory-outcomes assessment.
“Crosstree’s specific knowledge of our market segment allowed them to precisely target potential buyers. Further, Crosstree guided management to the right “value drivers” for each potential buyer, optimally tuning our various presentations, and ultimately driving enhanced valuations during the auction process."
-Doug Engfer, Founder, President and CEO
"The Board of Directors laid out clear expectations in its mandate for Crosstree. Management and the investors spent more than a decade building an industry leader, and it was not only important that we realized a good return, but also that we found good stewards of the asset and its employees. We set the bar pretty high and Crosstree persevered in helping secure an exit that was beneficial to all the key stakeholders.”
-John Hall, Director
invivodata
invivodata (www.invivodata.com) is a fully-integrated Clinical Outcome Assessment (COA) organization delivering regulatory-proven strategic consulting and practical electronic solutions to biopharmaceutical companies who depend upon patient-centered research. From reliable and scientifically sound consulting that helps research teams effectively develop, execute, and document COA strategies to electronically collecting COA data in global clinical development programs, invivodata helps its customers strategically use patient, clinician, and observer reported outcomes data (PROs, ClinROs & ObsROs) to support labeling claims, enhance reimbursement strategies, and meet other clinical program objectives. Through partnerships with leading CROs and eClinical technology providers, invivodata seamlessly integrates into the clinical trial ecosystem, helping to minimize operational risk and maximize efficiencies.
ERT
ERT (www.ert.com) is a global technology-driven provider of health outcomes research services supporting biopharmaceutical sponsors and Contract Research Organizations (CROs) to achieve their drug development and healthcare objectives. ERT harnesses leading technology coupled with reliable processes and scientific expertise to collect, analyse and report on clinical data to support the determination of health outcomes critical to the approval, labeling and reimbursement of pharmaceutical products. ERT is the acknowledged industry leader in centralized cardiac safety, respiratory efficacy services, electronic Patient Reported Outcomes (ePRO) and Clinical Outcome Assessment solutions.
Genstar Capital
Genstar Capital (www.gencap.com) is a leading private equity firm that has been actively investing in high quality companies for more than 20 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of operating executives and strategic advisors to transform its portfolio companies into leading industry businesses. Genstar has more than $3 billion of committed capital under management and targets investments focused on selected sectors within the life science, healthcare services, software and software services, insurance and financial services, and industrial technology industries.
The Crosstree Capital Partners Pharma Outsourcing...
The Crosstree Capital Partners Pharma Outsourcing...
